Is Molecular Cell Indexed in PubMed? Yes, and MEDLINE Is Active
Molecular Cell is indexed in PubMed and currently indexed for MEDLINE, which matters because mechanistic papers often need to reach disease, genomics, and broader cell-biology audiences.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Molecular Cell at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 16.6 puts Molecular Cell in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~13% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: Molecular Cell takes ~3-5 day. A faster-turnaround journal may suit a grant or job deadline better.
- If OA is required: gold OA costs $10,400 USD. Check institutional agreements before submitting.
Quick answer: yes. Molecular Cell is indexed in PubMed and currently indexed for MEDLINE from volume 1, issue 1 in December 1997. That gives it a clean launch-to-index profile.
The more useful interpretation is that a paper accepted here is not confined to one narrow cell-biology audience. PubMed indexing helps it move into adjacent disease-mechanism, genomics, and broader molecular-biology workflows.
Direct answer
If you publish in Molecular Cell, your paper is discoverable in PubMed and the journal remains actively indexed for MEDLINE.
NLM field | What the record shows | Why it matters |
|---|---|---|
publication start year | 1997 | the title is modern but established |
PubMed coverage | v1n1, Dec. 1997- | searchable from launch |
MEDLINE coverage | v1n1, Dec. 1997- | curated indexing also starts from launch |
current indexing status | Currently indexed for MEDLINE | active indexing is intact |
current subset | Index Medicus | standard medical-scientific subset support |
broad subject terms | Cell Biology; Molecular Biology | the record reflects the journal's cross-field mechanistic role |
That is a clean indexing record for a Cell Press mechanistic biology flagship.
Why this matters for Molecular Cell
Strong Molecular Cell papers often need to reach several adjacent audiences:
- molecular and cell biologists
- chromatin, RNA, and gene-regulation readers
- disease-mechanism researchers
- genomics and systems-biology groups
Those readers often search by protein, pathway, regulatory process, complex, or disease context rather than by opening the journal homepage directly. PubMed indexing matters because it helps a mechanistic paper move into those neighboring fields instead of staying trapped in one subfield conversation.
That matters more than some authors first assume. A paper in Molecular Cell often succeeds partly because it gets read beyond the immediate method or pathway niche.
What the indexing record tells you in practice
Practical question | What the record tells you |
|---|---|
will a new paper be visible in PubMed? | yes |
is the title actively indexed for MEDLINE? | yes |
did both lines start from launch? | yes |
is there archive weirdness to decode? | not much |
does this prove the manuscript belongs in Molecular Cell? | no |
That last answer is still the one that matters most for submission strategy.
PubMed versus MEDLINE for a mechanistic biology journal
For Molecular Cell, the distinction is simple but still useful:
- PubMed means the paper is discoverable in the main biomedical search system.
- MEDLINE means the title is actively inside the curated NLM journal index.
Because both lines start together from launch, the database side of the story is clean. The harder part is not whether the paper can be found. It is whether the paper deserves the journal's audience.
How this compares with nearby journals
Journal pattern | What the indexing record usually supports | What it does not solve |
|---|---|---|
mechanistic flagship like Molecular Cell | strong discoverability across cell and molecular biology | whether the work has enough causal closure |
broader cell-biology journal | wide reach across experimental biology | whether the work is too mechanism-heavy |
narrower specialty journal | targeted discovery within one technical area | broader cross-field reach |
So yes, the indexing record is strong. It still does not tell you whether the manuscript is complete or consequential enough for the venue.
How to verify the record yourself
To verify the record directly:
- open the NLM Catalog record
- confirm the PubMed line
- confirm the MEDLINE line
- check Current Indexing Status
- run a journal-title search in PubMed
For this title, the manual check is short because the launch-to-index continuity is straightforward.
What we see in PubMed-indexing questions for Molecular Cell
For PubMed-indexing questions for Molecular Cell, three patterns come up repeatedly.
The mechanism-is-enough mistake. Authors sometimes assume that if a mechanistic paper is technically strong and the journal is well indexed, the venue choice is solved. It is not. The paper still has to feel broad enough and important enough for Molecular Cell.
The cross-field underestimate. We often see authors underrate how much Molecular Cell papers need to travel into disease biology, genomics, and broader molecular biology after publication. PubMed indexing matters because that is how those readers actually discover the work.
The indexing-equals-fit shortcut. Another common error is treating a clean launch-to-index record as if it were evidence that the manuscript belongs there. The metadata says the paper will be visible. It says nothing about editorial bar.
That is the useful information gain here. The discoverability story is strong and simple, but it still does not answer the fit question.
What the NLM record means in practice for authors
The Molecular Cell NLM record tells you the title has been cleanly embedded in the biomedical search system since launch. If your paper is accepted, discoverability is not the weak point.
That matters because Molecular Cell papers often become reference points outside their original technical neighborhood. They are cited by readers following gene regulation, chromatin, RNA biology, signaling, and disease mechanism. PubMed indexing helps that movement happen.
But again, the NLM record does not tell you whether the manuscript has enough mechanistic closure, depth, or conceptual consequence for the journal. That judgment still has to be made separately.
Why this matters when comparing Molecular Cell with narrower mechanism journals
One practical reason authors ask this question is that they are choosing between Molecular Cell and a more specialized venue. In that comparison, PubMed indexing is usually not the differentiator. Both journals may be searchable. The useful distinction is that a Molecular Cell paper is often trying to travel further across neighboring mechanistic communities after publication.
That is why the clean launch-to-index record still matters. It supports the broader circulation pattern the journal is trying to earn, even though it does not by itself prove the manuscript deserves that wider audience.
What indexing does and does not tell you
This page answers the discoverability question. It does not answer whether the manuscript is mechanistically complete enough or broad enough for Molecular Cell.
Indexing tells you:
- the paper will be visible in PubMed
- the journal is actively indexed for MEDLINE
- the record is clean from launch
Indexing does not tell you:
- whether the causal story is complete enough
- whether the work has enough cross-field consequence
- whether a narrower mechanistic venue would be better
That is why the more useful next pages are:
If the fit question is what you actually need answered, a Molecular Cell submission readiness check is the right next step before submission.
Submit If / Think Twice If
Use this indexing answer as enough reassurance if:
- your concern is whether a published paper will be searchable
- you want confirmation of active MEDLINE indexing
- you need a clean answer on launch-to-present indexing continuity
Think twice if:
- you are treating indexing as a substitute for editorial fit
- the manuscript may still be too narrow or too incomplete for the venue
- what you really need is a mechanistic-bar judgment, not a discoverability check
If the fit question is what you actually need answered, a Molecular Cell submission readiness check gives you a manuscript-specific signal before you submit.
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Practical verdict
Yes, Molecular Cell is indexed in PubMed and currently indexed for MEDLINE, with both lines starting from launch in December 1997.
If your question is whether a published paper will be visible in the main biomedical search workflow, the answer is yes. If your real question is whether the manuscript deserves a Molecular Cell audience rather than a narrower mechanistic venue, that is a separate editorial-fit decision.
Or see example reports before you finalize.
Frequently asked questions
Yes. Molecular Cell is indexed in PubMed and currently indexed for MEDLINE according to the NLM Catalog.
Yes. The NLM Catalog shows PubMed and MEDLINE coverage from volume 1, issue 1 in December 1997.
Because Molecular Cell papers often need to reach disease-mechanism, genomics, and broader molecular-biology readers through search-driven workflows.
Open the journal’s NLM Catalog record, check the MEDLINE and PubMed lines plus current indexing status, then confirm recent Molecular Cell articles appear normally in PubMed.
Sources
- 1. Molecular Cell NLM Catalog record, NLM.
- 2. NLM Catalog help: current indexing status, NLM.
- 3. Molecular Cell journal homepage, Cell Press.
- 4. Molecular Cell guide for authors, Cell Press.
- 5. Molecular Cell in PubMed, PubMed.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- Molecular Cell Submission Guide
- How to Avoid Desk Rejection at Molecular Cell
- Is Molecular Cell a Good Journal? Impact, Scope, and Fit
- Is Your Paper Ready for Molecular Cell? The Mechanism-First Standard
- Molecular Cell 'Under Review': What Each Status Means and When to Expect a Decision
- Cell Metabolism vs Molecular Cell
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.